What is ADR?
ADR (Adverse Drug Reaction), czyli niepożądana reakcja na lekis any harmful and unintended response to a medicinal product that occurs when it is used at standard doses for treatment or prevention.
📖 Examples of ADRs:
✔ Nausea
✔ Rash
✔ Headache
✔ More serious side effects
Any reaction that was not intended may be classified as an ADR and requires monitoring.
Why is ADR monitoring so important?
In clinical trials, careful monitoring of adverse drug reactions is crucial for ensuring participant safety and assessing the risks associated with a new medicinal product.
Did you know?
Sometimes ADRs can lead to the discovery of new medical uses for existing drugs!
Example: Minoxidil, pierwotnie stosowany na nadciśnienie, okazał się skuteczny w… stimulating hair growth.. 🧴👩🦱
Find out more in our post on Instagram.
What is an AE?
An Adverse Event (AE), czyli Zdarzenie Niepożądaneis any unfavorable medical occurrence experienced by a clinical trial participant during the use of an investigational product, regardless of its relationship to the study drug.
Examples of AEs include:
✔ Headache
✔ Fever
✔ Rash
Any deviation from the participant’s pre-study health condition may be considered an AE.
What is an SAE?
A Serious Adverse Event (SAE), czyli Poważne Zdarzenie Niepożądaneis an AE that meets at least one of the following criteria:
🕊 Leads to death
💔 Is life-threatening
🏥 Requires hospitalization or prolongation of existing hospitalization
🧠 Results in significant or persistent disability/incapacity
👶 Causes a congenital anomaly or birth defect
What is the difference between AE and SAE?
Every SAE is an AE, but not every AE is an SAE. The key differentiating factor is the severity of the event and its impact on the participant’s health.
Why is rapid SAE reporting important?
Prompt reporting of serious adverse events allows researchers to assess the safety of the investigational product and take appropriate protective actions for study participants. It is a key component of risk monitoring in clinical trials.
Find out more in our post on Instagram.
Definition
“Affirmative agreement of a minor to participate in a clinical trial. The absence of expression of agreement or disagreement should not be interpreted as assent.”
Active consent (assent) refers to the conscious and explicit confirmation by a minor of their willingness to participate in a clinical trial. The lack of expressed agreement or disagreement cannot be considered as consent.
The Role of Assent in Clinical Trials
The process of obtaining assent should be tailored to the child’s age and level of maturity. Although a minor’s assent does not replace the formal consent required from legal representatives (parents or guardians), it remains a crucial element of ethical clinical research. It demonstrates the child’s understanding of the study and their willingness to cooperate.
Legal Regulations Concerning Assent
📜 ICH GCP E6(R3), section 2.8.12::
“When a minor is to be enrolled as a subject, information appropriate to their age and understanding should be provided and discussed during the assent process.
The minor’s affirmative agreement should be obtained before participation, whenever feasible.
If the subject reaches the age of legal consent during the study, informed consent should be sought in accordance with applicable regulations.”
In Poland, the participation of minors in clinical trials is regulated by:
✔ Art. 25 of the Act on the Profession of Physician and Dentist
✔ Art. 37h of the Pharmaceutical Law
According to these regulations, the participation of a child in a medical experiment is permitted only with the written consent of a legal representative.In the case of younger children, formal written consent is not required, but obtaining verbal assent, adjusted to the child’s age and maturity, is recommended. If the minor reaches the age of majority during the study, their own written consent must be obtained for continued participation.
Find out more about this topic in our post on Instagram.
The Importance of Audits in Clinical Research
An audit in clinical trials is not only a regulatory requirement, but above all, a tool to ensure participant safety and the high quality of collected data. Verifying compliance with Good Clinical Practice (GCP) guidelines and applicable regulatory requirements is essential for maintaining the reliability and credibility of study results.
Key Aspects of Auditing According to GCP (R3 version)
Data Sources
In the audit process, it is crucial that data sources meet the following criteria:
They are attributable, legible, contemporaneous, original, accurate, and complete.
Every change is properly tracked (audit trail), ensuring transparency and maintaining the integrity of original records.
Properly maintained documentation is the foundation of reliable and verifiable clinical trial results.
Risk-Based Auditing
The audit should be conducted in a manner proportionate to the risk associated with the specific clinical trial. Independent and qualified auditors, following a predefined plan, verify that all trial processes comply with protocol requirements, GCP standards, and applicable legal regulations.
Audit procedures may include:
On-site audits
Remote audits
Audit results are documented, ensuring full transparency of actions and enabling the effective implementation of corrective measures.
The Role of Auditing in Quality Assurance
Auditing not only identifies potential issues but also supports continuous improvement in clinical research. It ensures that every observation related to a study participant is recorded according to the highest quality standards.
Auditing plays a key role in building trust among patients, investigators, and research institutions, ensuring that study procedures comply with international regulations and ethical standards.
Regulatory Basis for Auditing in GCP (R3)
Paragraph 2.12.2 – defines the principles of transparency and integrity of data sources in clinical trials.
Paragraph 3.11.2 – concerns procedures related to auditing and its adaptation to the level of risk.
Adherence to these rules guarantees that all research processes are conducted in accordance with the highest standards of quality and ethics.
Find out more in our post on Instagram:
Blinding in Clinical Trials
Blinding (masking) is the process of concealing information about the treatment assignment (e.g., active treatment vs. placebo) from one or more parties involved in a clinical trial. The goal is to eliminate cognitive and subjective biases that could affect the interpretation of study results.
📜 ICH-GCP 1.10: “Blinding/masking – A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s).”
Why Do We Use Blinding?
The absence of blinding may lead to:
✔ Placebo/nocebo effect – participants perceive improvement or side effects simply because they expect them.
✔ Investigator bias – unintentional favoring of one study group.
✔ Distortion of results – subjective data analysis if treatment assignments are known.
Types of Blinding
🔹 Single-blind – the participant does not know the treatment assignment.
🔹 Double-blind – both the participant and the investigator are unaware of the assignment.
🔹 Triple-blind – an additional data analyst also remains unaware of group allocation.
How Is Blinding Conducted?
🔬 In pharmacological studies, the following methods are used:
✔ Placebo – identical in appearance to the active drug, making the therapy indistinguishable.
✔ Double-dummy – participants receive both the active drug and placebo versions to maintain blinding.
✔ Active placebo – mimics side effects so the participant cannot guess the treatment assignment.
Summary
Blinding is a key element of clinical trial methodology, protecting results from subjective influence and bias. Proper blinding ensures the reliability of planning, data collection, and the validity of conclusions by minimizing the risk of unmasking treatment assignments.
Find out more in our post on Instagram:
The Role and Importance of the Case Report Form (CRF) in Clinical Trials
In the digital era, data management in clinical research plays a crucial role in ensuring quality, safety, and regulatory compliance. One of the fundamental tools for collecting and reporting study data is the Case Report Form (CRF).
CRF Definition According to GCP E6(R3)
“Case Report Form (CRF): A tool for data collection, designed to record protocol-required information that investigators report to the sponsor for each trial subject.”
Why Is eCRF So Important?
Data Standardization
The Electronic Case Report Form (eCRF) enables standardized data collection, making it easier to analyze and compare results between different study sites.
Study Process Documentation
Detailed entries in the eCRF reflect every stage of the clinical trial, which is key for assessing the efficacy and safety of therapies. Every change is tracked, ensuring data transparency and integrity.
Source for Data Analysis
Data collected in the eCRF serve as the basis for statistical analyses that support clinical and regulatory decisions on the safety and effectiveness of investigational products.
Popular eCRF Systems Used in Clinical Trials
Currently, the market offers numerous platforms supporting electronic data capture (EDC) in clinical research. The most widely used include:
Veeva Vault CDMS – A comprehensive solution integrating data collection and analysis processes.
Medidata RAVE – An advanced platform supporting both small and large clinical trials.
Oracle Health Sciences – A system focused on safety and regulatory compliance.
eCRF.biz™ – An integrated platform eliminating the need for paper forms.
Flex Databases – A scalable CTMS system with a built-in eTMF, tailored for the needs of CROs, pharmaceutical, and biotechnology companies.
Summary
eCRF systems play a crucial role in modern clinical research, ensuring precise, regulatory-compliant, and easily accessible data.
Their growing popularity and technological advancement make them an indispensable part of the research process, improving the effectiveness and safety of clinical trials.
Find out more in our post on Instagram.
📄 Certified Copy in Clinical Trials – What You Need to Know
In clinical trial documentation compliant with GCP (Good Clinical Practice), it is crucial to determine whether a copy of a document can replace the original.If so, it must meet the requirements of a certified copy.
What Does GCP Say?
📌 GCP C.2.9:
„When a copy is used to permanently replace the original essential record, the copy should fulfil the requirements for certified copies.”
📌 Definition – Certified Copy:
„A copy (irrespective of the type of media used) of the original record that has been verified (i.e., by a dated signature or by generation through a validated process) to have the same information as the original, including relevant metadata, where applicable.”
What Does It Mean in Practice?
If the original document is replaced with a copy, that copy must:
Contain the same information as the original (e.g., patient name, diagnosis, treatment method).
Be certified by an authorized person – for example, the investigator, with a dated signature.
Include relevant metadata, such as the date of issue, document author, and source of origin.
Clinical Example
A patient provides medical records from a dermatology clinic to confirm eligibility criteria for an atopic dermatitis (AD) study.
For this documentation to be recognized as a source document, it must meet the above requirements. Otherwise, if it is not certified, it cannot replace the original.
What Should a Monitor Pay Attention To?
Does the document contain complete and key data?
Does it come from an authorized source (e.g., medical facility)?
Is the copy free from unauthorized changes or missing information?
A document that does not meet certified copy requirements should not be considered equivalent to the original in trial documentation.
📌 Find out more in our post on Instagram.
📄 Clinical Trial under GCP R3 – New Definition and Standards
With the implementation of the new ICH E6(R3)guidelines in July 2025, both sponsors and clinical research staff will need to comply with updated GCP certification standards. This is a significant change, especially for individuals building their careers in clinical research.
New Definition: Clinical Trial
According to GCP R3, a clinical trial is any interventional study conducted in humans with the aim of:
discovering or verifying clinical, pharmacological, or pharmacodynamic effects of an investigational product,
identifying adverse reactions,
studying the absorption, distribution, metabolism, and excretion of an investigational medicinal product,
…a wszystko to w celu oceny jego safety and efficacy..
What Does It Mean in Practice?
Nowa definicja rozszerza zakres pojęcia “badanie kliniczne”. Dotyczy to nie tylko testowania nowych cząsteczek, ale także:
biosimilar therapies,
advanced therapies (gene, cell, or tissue-based treatments).
The new standards also emphasize:
data digitalization and auditability,,
process transparency,
risk management,,
and continuous safety monitoring of participants.
How to Prepare for GCP R3?
📌 Update your GCP knowledge – understand the differences between versions R2 and R3.
📌 Ensure your training and certifications meet the new requirements.
📌 Prepare for increased expectations regarding data quality and safety oversight.
📌 If you work as a CRA, CTM, or Study Nurse – or are just starting your clinical research career – stay informed and adapt to the new standards now.
📌 Find out more in our post on Instagram.
📄 Dlaczego nie każdy lek w badaniu to “badany produkt”? Poznaj rolę comparatora w badaniach klinicznych
In clinical trials, the term comparatorappears frequently in protocols, SOPs, and CRFs — yet it is not always used correctly. In light of the new the GCP R3 guidelines, it’s worth clarifying this definition.
What Is a Comparator?
According to GCP R3:
Comparator – a medicinal product or placebo already authorized for use, employed as a reference in a clinical trial.
This means that a comparator is a substance or product against which the investigational product is compared. It can be either an approved medicinal product or a standard therapy used in clinical practice.
Types of Comparators
Placebo – a substance without an active ingredient, used to measure the effect of the investigational drug.
Active comparator – an approved medicinal product used to evaluate the efficacy and safety of the investigational drug.
– a standard clinical practice or therapy typically administered to patients with a given condition. – standardowa praktyka kliniczna, stosowana w danym wskazaniu zamiast konkretnego produktu porównawczego.
Example from Clinical Practice
A new antidiabetic drug is being tested and compared with metformin, an already approved treatment for type 2 diabetes. In this case, metformin functions as the comparator.
Why Is This Concept Important?
✔️ It influences protocol design and overall trial planning.
✔️ It appears throughout study documentation: CRFs, SOPs, and protocols.
✔️ It defines the context in which efficacy and safety of the investigational product are assessed.
Studies with an active comparator are more methodologically demanding, but for regulatory agencies they have higher evidential value – they demonstrate whether the new product works better or equally effectively compared to existing therapies.
📌 Find out more in our post on Instagram.
📄 What Is Compliance in Clinical Trials? Key Definition from GCP R3
In the latest version of the Good Clinical Practice (GCP R3) guidelines, the term compliance appears as many as 36 times – and not by accident. This term plays a fundamental role in ensuring the quality and reliability of clinical trial data.
What Does Compliance Mean?
In the context of clinical research, compliance refers to strict adherence to applicable requirements – both regulatory and ethical. This includes:
requirements arising from the protocol,
GCP principles,
local and international legal regulations.
According to the GCP R3 definition:
Compliance (in relation to trials):
Adherence to the trial-related requirements, GCP requirements, and the applicable regulatory requirements.
In other words, compliance is the practical implementation of principles that ensure the safety of participants and the integrity of research data.
Case Study Example
During an audit of a clinical trial site, irregularities were found in reporting adverse events. The personnel did not report all events in accordance with the protocol – detailed information regarding the duration, severity, and corrective actions was missing.
Consequences:
Violation of participant safety,
Loss of trust in data quality,
Risk of sanctions from regulatory authorities.
This is a typical example showing how lack of compliance can pose a serious threat to the proper conduct of a clinical trial.
Why Is Compliance So Important?
Ensures participant safety and well-being,
Guarantees data reliability and credibility,
Protects against regulatory and ethical consequences,
Impacts the overall quality and supervision of the study.
📌 Find out more in our post on Instagram.
📄 Confidentiality in Clinical Trials – What Does It Mean in Practice?
In clinical research, the principle of confidentiality is not just a formality – it is one of the key pillars of ethical and lawful clinical trial conduct. Without maintaining confidentiality, there can be no trust between patients, sponsors, ethics committees (EC), and regulatory authorities (RA).
What Does GCP R3 Say?
Confidentiality:
Prevention of disclosure to other than authorised individuals of a sponsor’s proprietary information or of a participant’s identity or their confidential information.
The principle of confidentiality requires preventing the disclosure of:
data that could identify a study participant,
confidential information about the participant,
information protected by the sponsor
…osobom nieuprawnionym do ich otrzymania.
Why Is Maintaining Confidentiality So Important?
Imagine a situation:
The study team sends an email with an attached test result that contains the patient’s name and surname.
As a result, there is a violation of personal data protection – a breach not only of GCP principles but also of GDPR regulations.
This may result in an inspection, warning, suspension, or even termination of collaboration with the site.
Case Study
During one of the large oncology trials, patient data was disclosed – one of the participants’ names was accidentally visible in a publicly accessible hallway report. As a result:
the research site received a warning letter,
the sponsor issued a formal reprimand.
Confidentiality Is Not Just a Procedure – It’s a Responsibility
Data protection principles should be implemented at every stage of the study, including:
internal communication within the team,
proper storage of both paper and electronic documentation,
data transfer between the sponsor and CRO,
document archiving and destruction processes.
Maintaining confidentiality is an essential element of daily work that directly impacts patient safety and the reputation of the entire research team.
📌 Find out more in our post on Instagram.
1. Introduction
Clinical trials are the foundation of medical progress, enabling the introduction of new, effective drugs to the market. A key role in ensuring the quality and safety of these studies is played by the Clinical Research Associate (CRA), also known as Clinical Trial Monitor.
2. Who Is a Clinical Research Associate (CRA)?
A Clinical Research Associate is a professional responsible for overseeing the progress of clinical trials, ensuring compliance with the protocol, regulations, and Good Clinical Practice (GCP) standards. The CRA acts as a link between the sponsor and the research site, ensuring the safety of participants and the reliability of study data.
3. CRA Responsibilities
The main duties of a Clinical Research Associate include:
- Monitoring visits:Regular site visits to assess compliance of study conduct with the protocol and applicable standards. These can also take place remotely (remote monitoring).
- Training of site staff:Providing guidance on the study protocol, reporting of adverse events, and adherence to GCP principles.
- Document verification: Checking the completeness and accuracy of data recorded in Case Report Forms (CRF) and compliance with source documentation.
- Patient safety oversight: Monitoring the process of reporting adverse events to ensure that serious adverse events are properly reported and documented.
- Reporting: Preparing monitoring visit reports and summaries, identifying irregularities, and providing feedback or recommendations to the study team.
4. Career Path and Required Qualifications
To become a Clinical Research Associate, one should have:
- Higher education: Preferably in medical, biological, pharmaceutical, or related fields.
- Knowledge of English: Most documentation and communication are conducted in this language.
- Interpersonal skills: Communicativeness, ability to work in a team and ability to solve problems are key.
- Attention to detail: Precision and thoroughness in verifying data and documentation.
- Mobility: Willingness for frequent business trips.
A career path often begins with positions such as Clinical Trial Assistant (CTA) or Clinical Research Coordinator (CRC), and then advances to higher positions such as Senior CRA or Clinical Project Manager.
5. Behind the Scenes of CRA Work
he work of a Clinical Research Associate is dynamic and full of challenges. It includes both office tasks and numerous visits to research sites. A typical day may look like this:
- Morning: Checking email, addressing current project-related issues, communicating with project teams and research sites.
- Noon : Preparing for a monitoring visit by reviewing data and reports, as well as reviewing visit notes. Preparing a confirmation letter to be sent to the research site with the agenda and planned activities for the visit.
- Afternoon:
- Project teleconference
- Meetings with project teams, discussion of project tasks and challenges
- Preparing a visit report, identifying potential issues, and proposing corrective actions
- Project/SOP trainings
- Settling business trip expenses
- Preparing payments for sites
- Booking accommodation or train/airline tickets for upcoming monitoring visits
- Around 17:00 or a bit later:
- Finishing work, packing a suitcase, laptop, and documentation.
Example monitoring visit schedule:
- 09:00 – Meeting with the site team; discussing study status and current issues
- 10:00 – Verification of study documentation (ISF)
- 11:00 – Checking patient documentation for consistency with CRF
- 14:00 – Pharmacy check: verification of investigational product (IP), drug logs and temperature forms
- 15:00 – Meeting with nursing staff: review of samples and laboratory materials
- 16:00 – Summary meeting with the investigator and study coordinator
- 17:00 – Completing systems and documentation
CRA work requires flexibility, excellent organizational skills, and the ability to work under time pressure. Despite the challenges, it provides satisfaction from participating in the process of introducing new therapies to the market and a real impact on improving patients’ quality of life.
Challenges and benefits of working as a Clinical Research Associate
The work of a Clinical Research Associate (CRA) brings both many benefits and challenges. Understanding both aspects is crucial for those considering a career in this field.
Challenges:
Frequent business trips: Monitors often visit different research sites, which may result in frequent travel and long periods away from home.
High responsibility: CRA is responsible for ensuring that the study is conducted in accordance with the protocol, regulations, and Good Clinical Practice (GCP) guidelines. Any errors may have consequences for the safety of study participants or data integrity.
Stress and time pressure: Deadlines, the need to make quick decisions, and working in a dynamic environment can be stressful.
Managing many tasks at the same time: Monitors often supervise several studies simultaneously, which requires excellent organizational and time management skills.
Benefits:
Attractive salary: The field of clinical research offers competitive remuneration.
Opportunities for career development: There is a clear career path — from junior positions to managerial roles, such as Senior CRA, Clinical Project Manager, or Director of Clinical Operations.
Dynamic and diverse work environment: CRA work combines office tasks with travel, teamwork, and direct contact with research sites, ensuring variety and continuous development.
Satisfaction from contributing to medical progress: Monitors play a key role in introducing new therapies to the market, which gives great personal satisfaction and contributes to the development of medicine.
7. Summary
The role of a Clinical Research Associate is crucial in ensuring the quality and safety of clinical trials. Although this work involves challenges such as frequent travel or high responsibility, it also offers numerous benefits, including attractive remuneration, career development opportunities, and satisfaction from having a real impact on the development of new therapies. For meticulous, communicative people who are ready for continuous improvement of their skills, a CRA career can be a fascinating and satisfying professional path.
📄 Data Integrity in Clinical Trials – the foundation of reliable results
Data integrity is one of the most important areas during all stages of clinical trials. According to the GCP R3guidelines, data must meet specific criteria to ensure the reliability and safety of the tested product.
Definition according to GCP R3
Data integrity includes the degree to which data fulfil key criteria of being:
attributable, legible, contemporaneous, original, accurate, complete, secure and reliable such that data are fit for purpose.
Data integrity is not an abstract concept — it is a practical standard that should be followed at every stage of preparing and reviewing study documentation.
Why is it so important?
Recent FDA reports have shown that over 60% of serious violations in clinical trials concerned errors in the area of data integrity.
Consequences:
questioning the reliability of study results,
risk of rejection or delay in registration application,
violation of GCP rules.
Examples from clinical trial practice
✅ Printout of ECG signed by the performer and dated - meets the criterion of attributable.
❌ Correction in documentation without signature and date - violates the principle of attributable i contemporaneous.
✅ Legible entry in the Source Document with date, signature and test result – meets the criterion of legible, original, accurate.
❌ Use of unclear abbreviations without explanation – data are not legible or interpretable.
❌ Blurred scan of the document – makes data verification impossible, violates the principle of reliable.
ALCOA++
The concepts included in the definition of data integrity can be associated with the ALCOA++ concept ALCOA++:
A – Attributable
L – Legible
C – Contemporaneous
O – Original
A – Accurate
Complete, Consistent, Enduring, Available
Maintaining consistency with these principles is necessary for data to be considered reliable in the light of GCP R3.
📌 Find out more in our post on Instagram.
📄 Direct Access in clinical trials – who has access to documentation and for what purpose?
In clinical research, the principle of Direct Access plays a key role in ensuring transparency, data quality, and participant safety. In the GCP R3 guidelines, the definition is as follows:
Direct Access:
Permission to examine, analyze, verify, and reproduce any records and reports that are important to the evaluation of a clinical trial…
This means that only authorized persons have access to clinical trial documentation – solely for the purpose of data control, quality, and participant safety.
Who can have direct access?
Clinical Research Associate (CRA) – for the purpose of monitoring compliance with the protocol and GCP.
Sponsor auditors – as part of internal quality assurance procedures.
Regulatory authorities - e.g. FDA, EMA, URPL, during inspections or regulatory investigations.
Each of these roles requires appropriate authorization and operates in accordance with personal data protection principles.
Why is direct access necessary?
Direct access allows:
comparison of source data (source documents) with entries in eCRF or other electronic systems,
assessment of the reliability and accuracy of data,
confirmation of compliance with GCP and regulatory requirements.
Without this process, it would not be possible to properly monitor and verify the course of a clinical trial.
Case Study
During an EMA inspection, the auditor requested access to the patient’s source documentation of a clinical trial conducted in a hospital. The inspection confirmed that the site provided access only to authorized persons and in accordance with confidentiality rules and personal data protection regulations.
Confidentiality principle
Although direct access allows the review of patient documentation, clinical trial participant data must always remain confidential. Persons obtaining access are obliged to maintain confidentiality and comply with regulations concerning personal data protection.
📌 Find out more in our post on Instagram.
📄 Computer system validation in clinical trials – the foundation of reliable data
In clinical trials, the quality and integrity of data are key – therefore, all computer systems that may affect participant safety or study results must be properly validated. In the GCP R3 guidelines, the detailed definition is as follows:
Computerised Systems Validation:
A process of establishing and documenting that the specified requirements of a computerised system can be consistently fulfilled from design until decommissioning of the system or transition to a new system. The approach to validation should be based on a risk assessment that takes into consideration the intended use of the system and the potential of the system to affect trial participant protection and the reliability of trial results.
What Does It Mean in Practice?
System validation is a process that confirms that the system:
meets specified requirements,
operates correctly and reproducibly,
is properly documented – from the design phase to decommissioning.
It does not apply only to computer systems such as eCRF – validation also covers auxiliary devices that affect the course of the study and data collection.
Examples of systems that require validation
eCRF / EDC – collect clinical data, must be fully validated.
Refrigerator with drugs – requires validation of the temperature recorder and temperature monitoring system.
Thermometer – must be calibrated to confirm correct storage conditions for drugs.
EMR (electronic medical record system) – must ensure data integrity and availability.
ePRO / eDiary applications – data entered by the patient must be protected and subject to validation.
Reminder system (SMS/mail) – if it affects compliance with the protocol, it is also subject to validation assessment.
Devices such as smartwatch / medical band – if data from them are analyzed, they must be validated.
Example from inspection practice
During one of the FDA inspections at a clinical site, the inspector did not ask, “Does the equipment work?”, but:
“Do you have documentation confirming that the equipment works in accordance with the requirements?”
This shows that validation documentation is just as important as the equipment or system itself.
Validation is not just a formality – it is one of the foundations of participant safety and data quality in clinical trials.
📌 Find out more in our post on Instagram.
📄 The role of CRO in clinical trials – what does GCP R3 say?
If you are planning a career in clinical research, knowing the role of a CRO (Clinical Research Organization) is absolutely essential. It is one of the most important entities supporting sponsors in conducting trials.
Definition according to GCP R3
Clinical Research Organization:
A service provider contracted by the sponsor to perform one or more of the sponsor’s trial-related activities and functions.
This means that CRO is a company contracted by the sponsor to perform certain activities related to a clinical trial. They may include both simple tasks and complex project management.
What can a CRO do?
The scope of CRO services is very wide. Example areas of activity:
conducting clinical trial monitoring (CRA),
pharmacovigilance management,
project management of research projects,
preparation and handling of registration documentation,
conducting quality audits,
managing clinical trial databases and statistics.
Despite outsourcing tasks to a CRO, the sponsor remains fully responsible for the clinical trial and must ensure compliance with all regulations and standards.
Interesting fact from industry history
The first CRO companies were established in the United States in the 1970s. Their goal was to support sponsors in conducting clinical trials and shortening the time of introducing new therapies to the market. Currently, the largest CROs operate globally, employing thousands of employees and conducting projects in over 100 countries.
Why is it worth knowing the role of a CRO?
It is one of the main employers in the clinical research sector.
Knowledge of the sponsor–CRO cooperation model is also essential for understanding the work of a CRA, CTA, or other operational roles.
Understanding the division of responsibilities helps better fulfill GCP obligations and ensure compliance with sponsor requirements.
📌 Find out more in our post on Instagram.